(6,11-dihydrodibenzothiepin-11-yl)methylamine | 82394-01-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: (6,11-dihydrodibenzothiepin-11-yl)methylamine
• 英文别名: 11-(Aminomethyl)-6,11-dihydrodibenzothiepin；6,11-Dihydrobenzo[c][1]benzothiepin-11-ylmethanamine
• CAS: 82394-01-2
• 化学式: C₁₅H₁₅NS
• 分子量: 241.357
• InChiKey: GELYKEDAAWAPIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (6,11-dihydrodibenzothiepin-11-yl)methylamine 在 N,N-二甲基乙酰胺 作用下， 以 氯仿 、 苯 为溶剂， 反应 5.67h， 生成 N-(6,11-dihydrodibenzothiepin-11-ylmethyl)-2-(4-methyl-1-piperazinyl)acetamide
  参考文献：
  名称：

  Valenta, Vladimir; Hulinska, Hana; Holubek, Jiri, Collection of Czechoslovak Chemical Communications, 1988, vol. 53, # 4, p. 860 - 869

  摘要：

  DOI：
• 作为产物：
  描述：

  11-chloro-6,11-dihydrodibenzothiepin 在 氨 、 氢气 、 镍 作用下， 以 乙醇 、 乙腈 为溶剂， 60.0~80.0 ℃ 、6.08 MPa 条件下， 反应 6.5h， 生成 (6,11-dihydrodibenzothiepin-11-yl)methylamine
  参考文献：
  名称：

  New triazine derivatives as potent modulators of multidrug resistance

  摘要：

  A series of 70 triazine derivatives have been synthesized and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity. Among the 12 selected compounds, 16 (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5-mu-M in DC-3F/AD and KB-A1 cells, respectively) and induced a strong accumulation of adriamycin. The relationship between the increase of ADR accumulation and the fold reversal induced by these compounds and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the P-glycoprotein (Pgp) catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators. In vivo, in association with the antitumor drug vincristine (0.25 mg/kg), 16 (100 mg/kg) increased the TIC by 39% in mice bearing the resistant tumor cell line P388/VCR. According to these interesting properties, 16 was selected for a clinical development because it was more bioavailable than 34, even though it was less active.

  DOI：

  10.1021/jm00091a017

文献信息

• (6,11-Dihydrodibenzo[b,e]thiepin-11-yl)methylamine, (4-methoxy-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-methylamine and derivatives; Synthesis and pharmacological screening
  作者：Vladimír Valenta、Jan Metyš、Miroslav Protiva

  DOI：10.1135/cccc19820984

  日期：——

  Using the Curtius reaction, the acids VIa and VIv were transformed to the carbamates IVa and IVb which afforded by alkaline hydrolysis the primary amines Ia and Ib. The N-methyl derivatives IIab were obtained by reduction of the carbamates IVa with lithium aluminium hydride. The N,N-dimethyl derivatives IIIab resulted by methylation of the primary amines Iab with formaldehyde and formic acid. The synthesis of the acid VIb was carried out from phthalide and 2-methoxythiophenol in seven steps. The amines Iab-IIIab showed clear thymoleptic properties in the test of reserpine ptosis in mice and by inhibition of the perphenazine catalepsy in rats. The acid VIb has antiinflammatory activity.

  使用Curtius反应，酸VIa和VIv转化为尿素酯IVa和IVb，通过碱性水解得到主要胺Ia和Ib。N-甲基衍生物IIab通过还原尿素酯IVa得到。N,N-二甲基衍生物IIIab通过用甲醛和甲酸对主要胺Iab进行甲基化得到。酸VIb的合成是从邻苯二甲酸酐和2-甲氧基噻吩在七个步骤中完成的。胺Iab-IIIab在小鼠对利血平致眼睑下垂试验中表现出明显的抗抑郁特性，并通过抑制对氯丙嗪对大鼠的猫状痉挛来展现。酸VIb具有抗炎活性。
• PROTIVA, MIROSLAV;VALENTA, VLADIMIR;HULINSKA, HANA;METYS, JAN;FRYCOVA, HA+
  作者：PROTIVA, MIROSLAV、VALENTA, VLADIMIR、HULINSKA, HANA、METYS, JAN、FRYCOVA, HA+

  DOI：——

  日期：——
• VALENTA, V.;METYS, J.;PROTIVA, M., COLLECT. CZECH. CHEM. COMMUN., 1982, 47, N 3, 984-993
  作者：VALENTA, V.、METYS, J.、PROTIVA, M.

  DOI：——

  日期：——
• VELENTA, V.;PROTIVA, M.;METYS, J.
  作者：VELENTA, V.、PROTIVA, M.、METYS, J.

  DOI：——

  日期：——
• VALENTA, VLADIMIR;HULINSKA, HANA;HOLUBEK, JIRI;DLABAC, ANTONIN;METYS, JAN+, COLLECT. CZECHOSL. CHEM. COMMUN., 53,(1988) N 4, 860-869
  作者：VALENTA, VLADIMIR、HULINSKA, HANA、HOLUBEK, JIRI、DLABAC, ANTONIN、METYS, JAN+

  DOI：——

  日期：——